The University Of Texas MD Anderson Cancer Center And Myriad Genetics Announce A 5-Year Strategic Alliance To Accelerate The Clinical Evaluation And Development Of Myriad's Molecular Residual Disease Assay
The University Of Texas MD Anderson Cancer Center And Myriad Genetics Announce A 5-Year Strategic Alliance To Accelerate The Clinical Evaluation And Development Of Myriad's Molecular Residual Disease Assay
德克薩斯大學MD安德森癌症中心與萬基遺傳宣佈建立爲期5年的戰略聯盟，以加速萬基的分子殘留病檢測的臨牀評估和開發。
The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad's molecular residual disease (MRD) assay.
德克薩斯大學MD安德森癌症中心與萬基遺傳公司今天宣佈建立五年戰略聯盟，以加速萬基的分子殘留病（MRD）檢測的臨牀評估和開發。
This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies to evaluate the clinical validity and utility of Myriad's Precise MRD.
這一戰略聯盟將萬基遺傳的長期腫瘤診斷經驗與MD安德森的臨牀和轉化研究專業知識相結合，以創建一系列研究，以評估萬基的精確MRD的臨牀有效性和實用性。
資訊熱榜
更新時間